US 11,793,872 B2
Modified MRNA vaccines encoding herpes simplex virus glycoproteins and uses thereof
Harvey Friedman, Merion, PA (US); Drew Weissman, Wynnewood, PA (US); Sita Awasthi, Bala Cynwyd, PA (US); and Gary Cohen, Havertown, PA (US)
Assigned to THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, Philadelphia, PA (US)
Filed by THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, Philadelphia, PA (US)
Filed on Jun. 17, 2021, as Appl. No. 17/349,929.
Application 17/349,929 is a continuation of application No. 16/640,008, granted, now 11,141,478, previously published as PCT/IB2018/056210, filed on Aug. 17, 2018.
Claims priority of provisional application 62/701,019, filed on Jul. 20, 2018.
Claims priority of provisional application 62/546,648, filed on Aug. 17, 2017.
Prior Publication US 2021/0386853 A1, Dec. 16, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/245 (2006.01); A61P 31/22 (2006.01); A61K 9/00 (2006.01); C07K 14/005 (2006.01); C12N 7/00 (2006.01); C12N 15/11 (2006.01); A61K 39/00 (2006.01)
CPC A61K 39/245 (2013.01) [A61K 9/0036 (2013.01); A61P 31/22 (2018.01); C07K 14/005 (2013.01); C12N 7/00 (2013.01); C12N 15/11 (2013.01); A61K 2039/53 (2013.01); A61K 2039/54 (2013.01); A61K 2039/57 (2013.01); C12N 2710/16622 (2013.01)] 25 Claims
 
1. A composition comprising (a) RNA encoding the ectodomain of Herpes Simplex Virus (HSV) glycoprotein D (gD), wherein the ectodomain consists of a sequence that is at least 98% identical to SEQ ID NO: 5, (b) RNA encoding the ectodomain of HSV glycoprotein C (gC), wherein the ectodomain consists of a sequence that is at least 98% identical to SEQ ID NO: 11, and (c) RNA encoding the ectodomain of HSV glycoprotein E (gE), wherein the ectodomain consists of a sequence that is at least 98% identical to SEQ ID NO: 17, wherein one or more of said RNAs is a nucleoside modified RNA.